Conspirituality cover image

Brief: The Promises & (Mostly) Perils of Ketamine Therapy

Conspirituality

00:00

The FDA Approval of Ketamine

A 2020 analysis published in the British Journal of Psychiatry concludes that we're just moving too fast with this intervention. The approved ketamine trials only lasted four weeks, and they barely showed efficacy above placebo. When Janssen stated that the problem wasn't esqueremin but the underlying conditions, the FDA accepted the reasoning even though no conclusive evidence was provided.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app